Tumour-associated myeloid cells (TAMCs) constitute a major component of the tumour microenvironment. Although some controversies persist in the precise description of the distinct subsets of this heterogeneous population, it is accepted that these cells promote tumour immunosuppression 7 . Recent studies support their contribution to the suppression of T cell function, which is not abolished by the use of ICB [8] [9] [10] [11] . To understand the association between resistance to ICB and myeloid cell infiltration, we compared multiple mouse tumour models treated with ICB. We show that mice bearing 4T1 breast carcinoma are resistant to anti-PD-1 (programmed cell death protein 1) or anti-CTLA4 (cytotoxic-T-lymphocyte-associated protein 4) therapy ( Fig. 1a and Extended Data Fig. 1 ). We observe that myeloid cells (CD11b +
. Growing evidence suggests that high infiltration of immune-suppressive myeloid cells correlates with poor prognosis and ICB resistance 5, 6 . These observations suggest a need for a precision medicine approach in which the design of the immunotherapeutic combination is modified on the basis of the tumour immune landscape to overcome such resistance mechanisms. Here we employ a pre-clinical mouse model system and show that resistance to ICB is directly mediated by the suppressive activity of infiltrating myeloid cells in various tumours. Furthermore, selective pharmacologic targeting of the gamma isoform of phosphoinositide 3-kinase (PI3Kγ), highly expressed in myeloid cells, restores sensitivity to ICB. We demonstrate that targeting PI3Kγ with a selective inhibitor, currently being evaluated in a phase 1 clinical trial (NCT02637531), can reshape the tumour immune microenvironment and promote cytotoxic-T-cell-mediated tumour regression without targeting cancer cells directly. Our results introduce opportunities for new combination strategies using a selective small molecule PI3Kγ inhibitor, such as IPI-549, to overcome resistance to ICB in patients with high levels of suppressive myeloid cell infiltration in tumours.
Tumour-associated myeloid cells (TAMCs) constitute a major component of the tumour microenvironment. Although some controversies persist in the precise description of the distinct subsets of this heterogeneous population, it is accepted that these cells promote tumour immunosuppression 7 . Recent studies support their contribution to the suppression of T cell function, which is not abolished by the use of ICB [8] [9] [10] [11] . To understand the association between resistance to ICB and myeloid cell infiltration, we compared multiple mouse tumour models treated with ICB. We show that mice bearing 4T1 breast carcinoma are resistant to anti-PD-1 (programmed cell death protein 1) or anti-CTLA4 (cytotoxic-T-lymphocyte-associated protein 4) therapy ( Fig. 1a and Extended Data Fig. 1 ). We observe that myeloid cells (CD11b + ) constitute the majority of CD45
+ tumour-infiltrating leukocytes (TILs) in this model (Fig. 1b) . This correlates with reduced CD8 + T cell infiltration and cytolytic function (Fig. 1b, c ). By contrast, B16-F10 melanoma tumours, which are more responsive to ICB (Fig. 1a and Extended Data Fig. 1 ), exhibit less myeloid cell infiltration but contain more activated CD8 + T cells (Fig. 1b, c) . Additionally, CD8
+ T cells express more granzyme B in the B16-F10 model. They also express higher levels of PD-1 and CTLA4 (Fig. 1c, data not shown) , which might explain their sensitivity to ICB. Furthermore, myeloid cells from 4T1 tumours or spleens suppress proliferation of T cells to a greater extent compared to myeloid cells from B16-F10 models ( Fig. 1d and Extended Data Fig. 1b ). These data suggest that TAMCs have varying phenotypes and are more suppressive in ICB-resistant tumours. Tumour-derived soluble factors such as granulocytemacrophage colony-stimulating factor (GM-CSF) help shape the tumour microenvironment by promoting myelopoiesis and recruitment of suppressive myeloid cells 12, 13 . To directly assess the ability of suppressive myeloid cells to induce resistance to ICB in the B16 melanoma, we used B16-F10 cells transduced with a GM-CSF expression construct (B16-GM-CSF) 14 . Tumours in this B16 model (B16-GM-CSF) become infiltrated by suppressive TAMCs and lose sensitivity to ICB compared to B16-F10 controls (Fig. 1a-d and Extended Data Fig. 1 ), indicating the critical role of suppressive myeloid cells in ICB resistance.
Kaneda et al. 15 and other previous studies 16, 17 have shown that PI3Kγ is highly expressed in myeloid cells and promotes migration and production of inflammatory mediators. Mice lacking the p110γ subunit of PI3Kγ show reduced tumour growth and immunosuppressive TAMCs 18 . We reasoned that pharmacological PI3Kγ inhibition might lead to an effective anti-tumour immune response and subvert ICB resistance caused by suppressive myeloid cells. To test this hypothesis, we used IPI-549, a selective PI3Kγ inhibitor in multiple tumour models 19 (Extended Data Fig. 2a ). IPI-549 treatment alone led to tumour growth inhibition in 4T1, B16-GMCSF, MC38, CT26, and LLC tumour models ( Fig. 2a and Extended Data Fig. 2b ). Lack of activity in tumours with few suppressive TAMCs (B16-F10, Fig. 2a ) suggests PI3Kγ inhibition affects myeloid cells and has no direct effect on tumour cells or other TILs. We also observe a significant reduction in lung metastasis after IPI-549-treatment (Fig. 2b) . TIL quantification shows no consistent differences in the total myeloid (CD11b (Fig. 2c) 20, 21 . When we analysed the myeloid cells with the above gating strategy in 4T1 TILs, we also observed that IPI-549 shifts myeloid cells towards the TAM-M1 population (Extended Data Fig. 3a) . Moreover, relative mRNA expression of M1 and M2 markers correlate with a less suppressive function of these cells (Extended Data Fig. 3b ). We subsequently tested the suppressive function of myeloid cells derived from IPI-549-treated B16-GMCSF tumour-bearing mice on naive CD8
+ T cell proliferation (Fig. 2e) . We show that suppression of CD8 + T cells is abolished in IPI-549-treated mice or when IPI-549 is added to the media. A similar functional observation was made in human myeloid suppressor cells in PBMCs (Extended Data Fig. 4b ) confirming its potential clinical use. In addition, pharmacodynamic evaluation of whole blood confirms the inhibition of PI3Kγ in monocytes after activation with a PI3Kγ stimulus in human volunteers (Extended Data Fig. 4a.) . To confirm that inhibition of PI3Kγ in myeloid cells is required to delay tumour progression, we depleted myeloid cells (anti-CD11b) before implanting LLC-Brei tumours in mice. Treatment with IPI-549 did not delay tumour growth in the absence of TAMCs (Extended Data Fig. 2e ). Taken together these findings suggest that PI3Kγ inhibition using IPI-549 is mainly effective in a tumour landscape rich in suppressive myeloid cells and allows for more precise delineation of patients in which it will potentially yield the greatest activity. The IPI-549-driven polarization of myeloid cells to a less immunosuppressive phenotype correlates with increased CD8 + T cell infiltrates and a higher CD8 + /regulatory T cell ratio at day 14 in both 4T1 and B16-GMCSF tumours (Fig. 3a) . CD8 + T cells expressed more granzyme B and proliferated more (Ki67 + ) in IPI-549 treated groups ( Fig. 3a and Extended Data Fig. 5a ). Along with these effector mechanisms, the expression of PD-1 and CTLA4 were enhanced in T cells ( Fig. 3a and Extended Data Fig. 5a ). Furthermore, in mice lacking T cells (RAG KO, Nu/Nu or after anti-CD8 + T cell depletion) the impact of IPI-549 was abrogated ( Fig. 3b and Extended Data Fig. 5b, c) . These findings confirm that targeting PI3Kγ enhances the T-cell-mediated antitumour activity by modifying the suppressive function of myeloid cells. We were concerned that targeting a key pathway in myeloid cells may affect their antigen presentation. Reassuringly, we found that IPI-549 did not reduce, but rather enhanced, the activation of tumour-antigenspecific T cells. This was demonstrated by the transfer of tumourantigen-specific cells (Pmel-1) in B16-GMCSF tumour-bearing mice (Fig. 3c ) and by ELISpot using cells isolated from CT26 tumour-bearing mice (Extended Data Fig. 5d ). Additionally, the proportion of effector memory cells (CD44
+ and CD4 + populations was not affected (Extended Data Fig. 6 ), suggesting that IPI-549 does not affect the ability of antigen-presenting cells to activate antigenspecific T cells. Taken together, these results demonstrate that selective PI3Kγ inhibition reduces the immune-suppressive function of myeloid cells, ultimately promoting T effector activation and T-cell-mediated cytotoxicity.
We found that treatment of myeloid-enriched tumours with IPI-549 leads to upregulation of PD-1 and CTLA4 expression on CD8
+ T cells ( Fig. 3a and Extended Data Figs 2d and 5a). This strongly suggests that + cells purified from 4T1, B16 and B16-GMCSF tumourbearing mice. Representative histograms of CD8 + T cell proliferation at corresponding CD8
+ to CD11b + T cell ratio (left panel) and quantification of CD8 + T cell proliferation using carboxyfluorescein succinimidyl ester (CFSE) dilution (right panel) (n = 3). Data represent analysis of n (shown above for each experiment) mice per group, mean ± s.e.m. Experiment were repeated at least twice to observe concordant statistical significance defined by P value: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (non-parametric Mann-Whitney U-test, log-rank (Mantel-Cox) test survival comparison). + T cells in CD45 + TILs and ratio of CD8 + /T reg (CD4 + FoxP3 + ) in CD45 + TILs in 4T1 and B16-GMCSF tumours at day 7 and 14 on treatment (n = 5). Right, quantification of granzyme B and PD1 expression in CD8 + TILs in 4T1 and B16-GMCSF tumours at day 7 and 14 on treatment. b, Mean tumour volume of intradermal B16-GMCSF tumours in IPI-549-versus vehicle-treated wild-type C57Bl6 (left) or Rag −/− mice (right) (n = 10). c, Flow cytometric analysis and quantification of gp-100 antigen-specific T cells transferred into IPI-549-or vehicle-treated B16-GMCSF tumour-bearing mice (n = 5). Data represent analysis of n (shown above for each experiment) mice per group, mean ± s.e.m. *P < 0.05, **P < 0.01 (non-parametric MannWhitney U-test).
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combining PI3Kγ inhibition with ICB therapy could yield additional anti-tumour activity. In fact, in the ICB-resistant 4T1 or B16-GMCSF models, the combination of either anti-CTLA4 or anti-PD-1 with IPI-549 significantly delayed tumour growth when compared to ICB alone (Fig. 4a-g ). We further confirmed this observation in the ICB-resistant LLC tumour model (Extended Data Fig. 7) . Analysis of TILs in the combination regimen of IPI-549 with PD-1 blockade shows that the addition of IPI-549 reduces immune suppression by increasing the M1/ M2 ratio, resulting in improved T cell effector function in 4T1 and B16-GMCSF tumours (Extended Data Fig. 8) . These results are similar to those reported by Kaneda et al. in which PD-1 blockade was combined with a dual PI3K inhibitor (γ/δ) 15 ; however, given the important effect of PI3Kδ in T cell function and more specifically regulatory T cells, it is unclear whether the observed anti-tumour drug effect in that study was myeloid-and/or T-cell-dependent. As CTLA4 and PD-1 have distinct immunologic mechanisms of action, greater therapeutic efficacy is achieved when both therapies are combined 22 . We tested the anti-PD-1 and anti-CTLA4 combination with IPI-549 in the 4T1 and B16-GMCSF models (Fig. 4a) . Double checkpoint blockade therapy alone did not result in any complete tumour regressions in 4T1 tumour-bearing mice and only 20% of the mice bearing B16-GMCSF tumours benefited from the therapy, further confirming multiple checkpoint resistance in these models. Notably, the addition of IPI-549 to the combination of anti-CTLA4 and anti-PD-1 was associated with complete remissions in 30% of 4T1-and 80% of B16-GMCSF tumour-bearing mice. Importantly, tumour-free survivors were resistant to tumour re-implantation (Extended Data Fig. 9 ), indicating long-lasting adaptive immunity.
Taken together, our data indicate that high infiltration by suppressive TAMCs promotes resistance to ICB, further confirming the complex, multi-factorial mechanisms of immune suppression in the tumour microenvironment. We show that modulating the suppressive phenotype of these cells towards a more inflammatory one can be achieved by selective pharmacologic targeting of the myeloid PI3Kγ isoform. By doing so, sensitivity to ICB can be effectively restored in TAMC-rich tumours. These findings provide a strong rationale to consider exploring PI3Kγ inhibition to overcome resistance to ICB in clinical trials based on a precision-medicine-type assessment of the tumour immune landscape. This hypothesis is currently being tested in the IPI-549 Phase I/Ib trial, as both a monotherapy and in combination with PD-1 blockade in solid tumours (clinicaltrials.gov identifier NCT02637531).
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. . CR, complete response defined as no visible or palpable tumour on consecutive measurements. d, Survival at 150 days of 4T1 tumour-bearing mice treated with anti-CTLA4 and anti-PD1 in combination with IPI-549 or vehicle compared to control (vehicle-treated only) (n = 10). e, Mean tumour volume of intradermal B16-GMCSF implants in anti-PD-1-, anti-CTLA4-or control-treated mice in combination with IPI-549 or vehicle (n = 10). f, Individual tumour volumes of intradermal B16-GMCSF implants in mice treated with anti-CTLA4 and anti-PD1 in combination with IPI-549 or vehicle (n = 10). g, Survival at 150 days of B16-GMSCF tumour-bearing mice treated with anti-CTLA4 and anti-PD1 in combination with IPI-549 or vehicle compared to control (vehicle-treated only) (n = 10). Data represent analyses of n (shown above for each experiment) mice per group, mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (non-parametric Mann-Whitney U-test or log-rank test).
METHODS
Cell lines. The murine cancer cell lines for melanoma (B16F10, referred to as B16), breast cancer (4T1) and colon cancer (CT26) were obtained from ATCC. The colon cancer cell line MC38 was obtained from the NCI and the lung cancer (LLC-Brei) from Caliper Life Sciences. Cells were maintained in RPMI medium supplemented with 10% fetal calf serum (FCS) and penicillin with streptomycin (complete RPMI media). The GMCSF-secreting B16 cell line (referred as to B16-GMCSF) has been reported and was used to increase the number of myeloid cells recruited to the tumour 14 . The cell lines have been mycoplasma tested. Quantitative RT-PCR. cDNA was prepared using 1 μg RNA with the qScript cDNA Synthesis Kit (Quanta Biosciences). Sybr green-based qPCR was performed using murine primers to Arg1, Ifng, Il10, Il12p40, Il1b, Il6, Ccl2, Gapdh, Nos2, Tgfb1, Tnfa, IL4ra, Indo, Ctla4, Pd-l1, CD86, CxCr2, Fizz1, Ymd1 (Qiagen QuantiTect Primer Assay). mRNA levels were normalized to Gapdh (ΔC t = C t gene of interest -C t Gapdh) and reported as relative mRNA expression
or fold change. Cytokine analysis. Tumours were excised, snap-frozen in liquid nitrogen, and pulverized using a tissue grinder. Tumour protein lysates were prepared in MSD Tris Lysis Buffer (Meso Scale Discovery, Rockville, Maryland) containing 2× Halt Protease and Phosphatase Inhibitor Cocktail (Fisher Scientific). Total protein concentration was normalized to 4 mg ml , PO) for 6 or 9 days. Tumours were isolated, and frozen until needed; tumours then thawed and RNA was extracted from all cells. RNA-seq was done at Expression Analysis (Q2 Solutions). Sequence reads were aligned to the mouse B38 reference genome using OmicSoft ArrayStudio and the UCSC gene model. log 2 and were provided by N. Restifo (National Cancer Institute, Bethesda, Maryland). All mice were maintained in micro-isolator cages and treated in accordance with the NIH and American Association of Laboratory Animal Care regulations. All mouse procedures and experiments for this study were approved by the Memorial Sloan Kettering Cancer Center Institutional Animal Care and Use Committee. No statistical methods were used to predetermine sample size. Ten to fifteen mice per treatment strategy were used to allow 90% power, and a 5% significance level, and detect differences in tumour-free survival from 10% to 80%. Typically, tumours grew in 100% of control animals. An additional 5 mice per group were used for tissue harvest at day 7 and day 14 on treatment. Mice cage and treatment allowance were randomized at day 7 after tumour implants. Tumour challenge and treatment experiments. On day 0 of the experiments, tumour cells were injected intradermally (i.d.) in the right flank. For the B16 model, 2.5 × 10 5 B16-WT or B16-GMCSF cells were injected into C57BL/6J mice. For 4T1 model and for the CT26 model, 5 × 10 5 cells were used subcutaneously in Balb/c mice. For studies in immune compromised mice, the CT26 study was done in the Balb/c NU/NU strain and the B16-GMCSF in C57Bl.6 Rag1 −/− mice. Mice were obtained from Jackson Labs and Charles River Labs. Treatments were given as single agents or in combinations with the following regimen for each drug. The PI3Kγ inhibitor drug IPI-549 was dissolved at 5% 1-methyl-2-pyrrolidinone in polyethylene glycol 400 and administered by oral gavage once a day at 15 mg kg −1 . Treatment was initiated on day 7 ending on day 21 post tumour implant. Control groups received vehicle (5% NMP, 95% PEG) without the active product. Anti-CTLA4 antibody (100 μg per mouse, clone 9H10, Bio X cell) and anti-PD-1 antibody (250 μg per mouse, clone RPM1-14, Bio X cell) were injected intraperitoneally (i.p.) on days 7, 10, 13 and 16 for the B16, B16-GMCSF and 4T1 models and on days 10, 13 and 16 for the CT26 model. Tumours were measured every second or third day with a calliper, and the volume (length × width × height) was calculated. Mice that had no visible and palpable tumours that could be measured on consecutive measurement days were considered complete regressions. Animals were euthanized for signs of distress or when the total tumour volume reached 2,500 mm , PO) and dosed every three days with 100 μg antibody, either isotope control or anti-CD8. Tumour measurements were taken every second or third day during the 13 days of dose administration. For CD11b + cell depletion, murine Lewis Lung Carcinoma tumour brei (here referred to as LLC) was propagated into ten C57BL/6 Albino male mice. When tumours reached an average of 1,500 mm 3 , tissue was collected and made into a single-cell suspension. Tissue was dissociated in a glass dunce, filtered through a 100 μm filter and washed with cold buffer of PBS pH 7.2, 0.5% BSA and 2 mM EDTA. An aliquot of cells was separated, and placed on ice until the time of re-transplant. Cells were counted and adjusted to 2 × 10 7 total cells. To deplete the CD11b cells from the tumour homogenate, CD11b micro beads (MACS #130-049-601) were added to the sample and incubated on ice for 15 min. Cells were washed and re-suspended with buffer. A negative depletion was preformed following the Miltenyi autoMACS protocol. The positive selected cells and starting tumour inoculum were counted and cell numbers adjusted to the tumour inoculum used for historical studies. , anti-Ki67 (clone B56), anti-CTLA4-APC (clone), anti-Granzyme B-PE-TR (clone GB11), antibodies, all purchased from BD Biosciences, eBioscience or invitrogen. For intracellular stain, cells were further permeabilized using a FoxP3 Fixation and Permeabilization Kit (eBioscience) and stained for Foxp3 (clone FJK-16 s, Alexa-Fluor-700-conjugated, eBioscience), Ki67 (clone SolA15, eFluor-450-conjugated, eBioscience) or CTLA4. The stained cells were acquired on a LSRII Flow Cytometer using BD FACSDiva software (BD Biosciences) and the data were processed using FlowJo software (Treestar). Dead cells and doublets were excluded on the basis of forward and side scatter and Fixable Viability Dye eFluor 506.
Purification of myeloid or CD8
+ T cells from tumours or spleen. Mouse tumour and spleen single-cell suspensions were generated as described in the previous section. Tumour cells were subsequently separated from debris over a Ficoll gradient (Sigma-Aldrich). B cells were depleted from splenocytes using CD19 microbeads and LD columns according to the manufacturer's instructions (Miltenyi Biotec) to enrich the myeloid fractions. Cells were stained with anti-CD45.2-AlexaFluor-700, anti-CD11b-APC-Cy7, anti CD8-PE antibodies for flow sorting on a FACSAria II Cell Sorter (BD Biosciences). Dead cells were excluded using DAPI (Invitrogen). Purity of flow-sorted populations was above 90%.
